Diffuse Large B-Cell Lymphoma Clinical Trials

A listing of 33 Diffuse Large B-Cell Lymphoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Diffuse Large B-Cell Lymphoma

1 - 12 of 33

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 33 active clinical trials seeking participants for Diffuse Large B-Cell Lymphoma research studies. The states with the highest number of trials for Diffuse Large B-Cell Lymphoma participants are California, New York, Ohio and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Trial

Crohn's Disease Clinical Study

Recruiting

Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.

Conditions:

Crohn's Disease

Crohn Disease

Crohns Disease

Crohn's Disease (CD)

Crohn Colitis

Learn More

Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

NCT06031194

Recruiting

This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/25/2025

Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Conditions: Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma

Learn More ›

Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

NCT04850495

Recruiting

This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-PolaCHP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed to block a protein called Bruton Tyrosine Kinase in order to stop cancer growth. R-CHOP is the acronym for the combination of five drugs: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. It is the most widely used chemoimmunother... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/21/2025

Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio +1 locations

Conditions: Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

Learn More ›

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

NCT03960840

Recruiting

This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

05/06/2025

Locations: University of California LA, Los Angeles, California +43 locations

University of California LA, Los Angeles, California

Stanford University Medical Center, Stanford, California

H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

Northside Hospital, Atlanta, Georgia

Northwestern University Northwestern Memorial Hospital Trans, Chicago, Illinois

Uni of Chi Medi Ctr Hema and Onco, Chicago, Illinois

University of Kansas Cancer Center, Westwood, Kansas

Mass Gen Hosp Cancer Center, Boston, Massachusetts

Montefiore Medical Center, Bronx, New York

Oregon Health Sciences University, Portland, Oregon

University of Pennsylvania Clinical, Philadelphia, Pennsylvania

Sarah Cannon Research Institute, Nashville, Tennessee

St Davids South Austin Medical Ctr, Austin, Texas

Uni Of TX MD Anderson Cancer Cntr, Houston, Texas

Medical College of Wisconsin, Milwaukee, Wisconsin

Novartis Investigative Site, Melbourne, Victoria

Novartis Investigative Site, Wien, Not set

Novartis Investigative Site, Marseille, Not set

Novartis Investigative Site, Paris 10, Not set

Novartis Investigative Site, Pierre Benite, Not set

Novartis Investigative Site, Rennes, Not set

Novartis Investigative Site, Frankfurt am Main, Hessen

Novartis Investigative Site, Leipzig, Sachsen

Novartis Investigative Site, Essen, Not set

Novartis Investigative Site, Koeln, Not set

Novartis Investigative Site, Bergamo, BG

Novartis Investigative Site, Bologna, BO

Novartis Investigative Site, Milano, MI

Novartis Investigative Site, Rozzano, MI

Novartis Investigative Site, Fukuoka city, Fukuoka

Novartis Investigative Site, Sapporo city, Hokkaido

Novartis Investigative Site, Bunkyo ku, Tokyo

Novartis Investigative Site, Cordoba, Andalucia

Novartis Investigative Site, Sevilla, Andalucia

Novartis Investigative Site, Salamanca, Castilla Y Leon

Novartis Investigative Site, Badalona, Catalunya

Novartis Investigative Site, Barcelona, Catalunya

Novartis Investigative Site, Hospitalet de LLobregat, Catalunya

Novartis Investigative Site, Valencia, Comunidad Valenciana

Novartis Investigative Site, Barcelona, Not set

Novartis Investigative Site, Madrid, Not set

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma

Learn More ›

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

NCT05660967

Recruiting

The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an antibody that has already been tested in several clinical studies. All patients will receive active treatment. There is an equal chance of receiving epcoritamab or epcoritamab plus lenalidomide.

Gender:

ALL

Ages:

75 years and above

Trial Updated:

05/05/2025

Locations: UW Cancer Center at ProHealth Care, Waukesha, Wisconsin +77 locations

UW Cancer Center at ProHealth Care, Waukesha, Wisconsin

Kepler Universitätsklinikum, Linz, Not set

LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Not set

Klinikum Wels-Grieskirchen GmbH, Wels, Not set

Institut Jules Bordet, Anderlecht, Not set

GZA Ziekenhuizen, Antwerpen, Not set

ZNA, Antwerpen, Not set

UZ Brussels, Jette, Not set

UZ Leuven, Leuven, Not set

AZ Delta, Roeselare, Not set

Vitaz, Temse, Not set

AZ Turnhout - Campus Sint-Elisabeth, Turnhout, Not set

Fakultni nemocnice Hradec Kralove, Hradec Králové, Not set

Vseobecna fakultni nemocnice v Praze, Praha 2, Not set

Fakultni nemocnice v Motole, Praha 5, Not set

CHU Angers - Hôpital Hôtel Dieu, Angers, Not set

Hôpital Henri Mondor, Créteil, Not set

Hopital Claude Huriez - CHRU Lille, Lille, Not set

Hopital de la Conception - APHM, Marseille, Not set

CHU de Nantes - Hotel Dieu, Nantes, Not set

Centre Antoine Lacassagne, Nice, Not set

Hôpital Saint-Antoine, Paris, Not set

Hôpital Saint-Louis, Paris, Not set

CHU de Bordeaux - Hôpital Haut-Lévêque, Pessac, Not set

CHU Amiens - Hopital Sud, Salouël, Not set

CHU Tours - Hôpital Bretonneau, Tours, Not set

Universitaetsklinikum Freiburg, Freiburg, Baden Wuerttemberg

Universitaetsklinikum Aachen AOeR, Aachen, Not set

Vivantes Klinikum Neukoelln, Berlin, Not set

Universitaetsklinikum Wuerzburg, Würzburg, Not set

Clinica di Ematologia AOU Ospedali Riuniti di Ancona, Ancona, Not set

IRCCS Centro di Riferimento Oncologico, Aviano, Not set

Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS, Bologna, Not set

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili), Brescia, Not set

Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo, Not set

IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" - IRST, Meldola, Not set

IEO Istituto Europeo di Oncologia Parent, Milano, Not set

Ospedale San Raffaele, Milano, Not set

Azienda Ospedaliera Vincenzo Cervello, Palermo, Not set

AUSL Piacenza Ospedale Guglielmo da Saliceto, Piacenza, Not set

Azienda sanitaria integrata università di Trieste, Trieste, Not set

Kyushu University Hospital, Fukuoka shi, Not set

Kagoshima University Hospital, Kagoshima, Not set

Kanazawa University Hospital, Kanazawa, Not set

National Cancer Center Hospital East, Kashiwa, Not set

Cancer Institute Hospital of JFCR, Koto-Ku, Not set

Matsuyama Red Cross Hospital, Matsuyama, Not set

NHO Nagoya Medical Center, Nagoya shi, Not set

Yamagata University Hospital, Yamagata, Not set

Kindai University Hospital, Ōsaka-sayama, Not set

Keimyung University Dongsan Hospital, Daegu, Not set

National Cancer Center, Goyang-si, Not set

Jeonbuk National University Hospital, Jeonju, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej, Biała Podlaska, Not set

Pratia MCM Krakow, Kraków, Not set

Centrum Medyczne Pratia Poznan, Skorzewo, Not set

MICS Centrum Medyczne Torun, Toruń, Not set

ICO Badalona - Hospital Universitari Germans Trias i Pujol, Badalona, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona, Not set

Hospital San Pedro de Alcantara, Cáceres, Not set

Hospital General Universitario Gregorio Marañon, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario Ramon y Cajal, Madrid, Not set

Hospital Universitario Nuestra Señora de Valme, Sevilla, Not set

Hospital Universitario Puerta del Mar, Sevilla, Not set

Hospital Universitario Virgen Macarena, Sevilla, Not set

Bristol Haematology and Oncology Centre, Bristol, Not set

Royal Marsden Hospital - Fulham, London, Not set

Churchill Hospital, Oxford, Not set

Derriford Hospital, Plymouth, Not set

Southampton General Hospital, Southampton, Not set

Royal Marsden Hospital, Sutton, Not set

Royal Cornwall Hospital NHS Trust, Truro, Not set

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103

Recruiting

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.

Gender:

ALL

Ages:

Between 6 months and 25 years

Trial Updated:

05/02/2025

Locations: Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora, Colorado +46 locations

Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora, Colorado

Yale-New Haven Hospital ( Site 1012), New Haven, Connecticut

Johns Hopkins All Children's Hospital ( Site 1025), Saint Petersburg, Florida

University of Iowa-Holden Comprehensive Cancer Center ( Site 1017), Iowa City, Iowa

Corewell Health ( Site 1001), Grand Rapids, Michigan

Children's Mercy Hospital ( Site 1024), Kansas City, Missouri

Rutgers Cancer Institute of New Jersey ( Site 1008), New Brunswick, New Jersey

New York Medical College ( Site 1023), Valhalla, New York

Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003), Fargo, North Dakota

Oregon Health and Science University ( Site 1004), Portland, Oregon

Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia, Pennsylvania

Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 1015), Sioux Falls, South Dakota

University of Texas MD Anderson Cancer Center ( Site 1007), Houston, Texas

Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City, Utah

Sydney Children's Hospital-Kids Cancer Centre ( Site 1997), Randwick, New South Wales

Queensland Children's Hospital-Oncology & Haematology ( Site 1996), Brisbane, Queensland

UZ Gent ( Site 1428), Gent, Oost-Vlaanderen

Hospital Erasto Gaertner-CEPEP - Pesquisa Clínica ( Site 1268), Curitiba, Parana

Hospital de Clinicas de Porto Alegre ( Site 1265), Porto Alegre, Rio Grande Do Sul

Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1264), Barretos, Sao Paulo

Fundação Faculdade Regional de Medicina de São José do Rio Preto-Centro Integrado de Pesquisa ( Site, São José do Rio Preto, Sao Paulo

Hospital Carlos Van Buren ( Site 1880), Valparaíso, Valparaiso

Rigshospitalet-Department of paediatrics and adolescent medicine, Section of Paed haem-onc ( Site 14, Copenhagen, Hovedstaden

CHU de Bordeaux. Hopital Pellegrin ( Site 1105), Bordeaux, Aquitaine

Gustave Roussy ( Site 1103), Villejuif, Ile-de-France

Centre Hospitalier Universitaire de Nantes - Hôpital Femme-Enfant-Adolescent Chu De Nantes ( Site 11, Nantes, Pays-de-la-Loire

CENTRE LEON BERARD-IHOPE (pediatrric oncology) ( Site 1100), Lyon, Rhone-Alpes

Universitätsklinikum Münster - Albert Schweitzer Campus-Pädiatrische Hämatologie und Onkologie ( Sit, Münster, Nordrhein-Westfalen

Semmelweis Egyetem ( Site 1838), Budapest, Not set

Rambam Health Care Campus-Pediatric Hemato-Oncology ( Site 1674), Haifa, Not set

Sheba Medical Center ( Site 1675), Ramat Gan, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori-Pediatric Oncology ( Site 1552), Milan, Lombardia

Ospedale Pediatrico Bambino Gesù IRCCS-Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica, Rome, Roma

Seoul National University Hospital-Pediatrics ( Site 1972), Seoul, Not set

Asan Medical Center-Pediatrics - Pedicatric Oncology ( Site 1973), Seoul, Not set

Prinses Maxima Centrum voor Kinderoncologie ( Site 1510), Utrecht, Not set

Hospital Sant Joan de Déu-Pediatric Oncology Department ( Site 1717), Esplugas De Llobregat, Barcelona

Hospital Infantil Universitario Niño Jesús-Servicio de Onco-Hematología Pediátrica ( Site 1715), Madrid, Madrid, Comunidad De

Hospital Universitari Vall d'Hebron-Servei de Hematologia i Oncologia Pediatrica ( Site 1716), Barcelona, Not set

Prövningsenhet barn, Sahlgrenska Universitetssjukhuset ( Site 1634), Gothenburg, Vastra Gotalands Lan

National Taiwan University Hospital ( Site 1983), Taipei, Not set

Hacettepe Universite Hastaneleri ( Site 1961), Ankara, Not set

Ankara Bilkent Şehir Hastanesi ( Site 1962), Ankara, Not set

Ege Universitesi Hastanesi ( Site 1963), İzmir, Not set

Royal Victoria Infirmary-Great North Children's Hospital ( Site 1348), Newcastle upon Tyne, England

University College London Hospital ( Site 1350), London, London, City Of

University Hospital of Wales ( Site 1346), Cardiff, Not set

Conditions: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma

Learn More ›

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

NCT05512390

Recruiting

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL)... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/01/2025

Locations: University of Arizona Cancer Center - Tucson /ID# 247752, Tucson, Arizona +14 locations

Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma

Learn More ›

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

NCT03223610

Recruiting

Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR). Objective: To study the safety of ViPOR for people with B-cell lymphoma. Eligibility: People ages 18 and older with B-cell lymphoma whose cancer has returned or not improved af... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/30/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma

Learn More ›

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

NCT05952024

Recruiting

The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.

Gender:

ALL

Ages:

Between 65 years and 99 years

Trial Updated:

04/29/2025

Locations: Research Site, La Jolla, California +51 locations

Research Site, La Jolla, California

Research Site, Orange, California

Research Site, Stamford, Connecticut

Research Site, Jacksonville, Florida

Research Site, Des Moines, Iowa

Research Site, Lexington, Kentucky

Research Site, Beltsville, Maryland

Research Site, Towson, Maryland

Research Site, Detroit, Michigan

Research Site, Sioux Falls, South Dakota

Research Site, Lubbock, Texas

Research Site, Olympia, Washington

Research Site, Tacoma, Washington

Research Site, Barretos, Not set

Research Site, Belo Horizonte, Not set

Research Site, Brasilia, Not set

Research Site, Campinas, Not set

Research Site, Curitiba, Not set

Research Site, Florianópolis, Not set

Research Site, Goiania, Not set

Research Site, Natal, Not set

Research Site, Porto Alegre, Not set

Research Site, Recife, Not set

Research Site, Ribeirão Preto, Not set

Research Site, Rio de Janeiro, Not set

Research Site, Sao Luis, Not set

Research Site, Sao Paulo, Not set

Research Site, Sorocaba, Not set

Research Site, São José do Rio Preto, Not set

Research Site, São Paulo, Not set

Research Site, Busan, Not set

Research Site, Daegu, Not set

Research Site, Gyeongsangnam-do, Not set

Research Site, Incheon, Not set

Research Site, Jeonju-si, Not set

Research Site, Seo-gu, Not set

Research Site, Seoul, Not set

Research Site, Suwon-si, Not set

Research Site, Ulsan, Not set

Research Site, San Juan, Not set

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

Recruiting

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxal... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/28/2025

Locations: Bass Medical Group ( Site 0166), Walnut Creek, California +90 locations

Bass Medical Group ( Site 0166), Walnut Creek, California

Innovative Clinical Research Institute ( Site 0122), Whittier, California

Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163), Boca Raton, Florida

Saint Elizabeth Medical Center Edgewood ( Site 0165), Edgewood, Kentucky

University of Kentucky Chandler Medical Center ( Site 0158), Lexington, Kentucky

Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133), Louisville, Kentucky

Louisiana State University Health Sciences Center New Orleans ( Site 0134), New Orleans, Louisiana

University of Maryland ( Site 0123), Baltimore, Maryland

Dana-Farber Cancer Institute-Lymphoma ( Site 0111), Boston, Massachusetts

University of Massachusetts Medical School ( Site 0119), Worcester, Massachusetts

St. Vincent Frontier Cancer Center-Research ( Site 0108), Billings, Montana

Atlantic Health System ( Site 0116), Morristown, New Jersey

New York Medical College ( Site 0113), Valhalla, New York

Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0156), Nashville, Tennessee

Hospital Aleman ( Site 2200), Buenos Aites, Caba

Instituto Alexander Fleming ( Site 2201), Caba, Not set

Hospital Privado Universitario de Córdoba ( Site 2202), Cordoba, Not set

Townsville University Hospital ( Site 1800), Douglas, Queensland

Grampians Health ( Site 1802), Ballarat, Victoria

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto, Ontario

Biocenter ( Site 2401), Concepcion., Biobio

IC La Serena Research ( Site 2405), La Serena, Coquimbo

Oncocentro Valdivia ( Site 2407), Valdivia., Los Rios

Clínica Inmunocel ( Site 2404), Santiago, Region M. De Santiago

Clínica RedSalud Vitacura ( Site 2409), Santiago, Region M. De Santiago

Bradfordhill ( Site 2403), Santiago, Region M. De Santiago

Beijing Cancer hospital ( Site 3000), Beijing, Beijing

Chongqing University Cancer Hospital-Medical Oncology ( Site 3025), Chongqing, Chongqing

Chongqing University Three Gorges Hospital ( Site 3026), Chongqing, Chongqing

Sun Yat-sen University Cancer Center-Internal Medicine ( Site 3001), Guangzhou, Guangdong

Zhujiang Hospital ( Site 3002), Guangzhou, Guangdong

The First Affiliated Hospital of Henan University of Science &Technology ( Site 3029), Luoyang, Henan

Henan Cancer Hospital-hematology department ( Site 3013), Zhengzhou, Henan

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 3017), Wuhan, Hubei

The First Affiliated Hospital of Nanchang University ( Site 3004), Nanchang, Jiangxi

Jiangxi Provincial Cancer Hospital ( Site 3005), Nanchang, Jiangxi

The First Hospital of Jilin University-Hematology ( Site 3012), Changchun, Jilin

Fudan University Shanghai Cancer Center ( Site 3009), Shanghai, Shanghai

West China Hospital of Sichuan University-Head and Neck Oncology ( Site 3016), Cheng Du, Sichuan

Sichuan Cancer hospital-Oncology ( Site 3021), Chengdu, Sichuan

Zhejiang Cancer Hospital ( Site 3014), Hangzhou, Zhejiang

Hospital Pablo Tobon Uribe ( Site 0804), Medellin, Antioquia

Instituto Médico de Alta Tecnologia S.A.S ( Site 0803), Monteria, Cordoba

FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Sit, Bogota, Distrito Capital De Bogota

Oncologos del Occidente ( Site 0800), Pereira., Risaralda

Fundacion Valle del Lili ( Site 0802), Cali, Valle Del Cauca

Hospital Metropolitano - Sede Lindora ( Site 2500), Santa Ana, San Jose

CIMCA ( Site 2501), San Jose, Not set

centre hospitalier lyon sud-Service Hématologie ( Site 0702), Pierre-Bénite, Rhone

Pitie Salpetriere University Hospital-Clinical haematology ( Site 0700), Paris, Not set

University Hospital of Alexandroupolis ( Site 0903), Alexandroupolis, Anatoliki Makedonia Kai Thraki

Evangelismos General Hospital of Athens ( Site 0900), Athens, Attiki

Regional General Hospital of Athens "Laiko" ( Site 0901), Athens, Attiki

MEDI-K ( Site 2602), Guatemala, Not set

Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 2601), Guatemala, Not set

CELAN,S.A ( Site 2603), Guatemala, Not set

Queen Mary Hospital ( Site 3100), Hong Kong, Not set

Princess Margaret Hospital ( Site 3101), Hong Kong, Not set

Emek Medical Center-Hematology Unit ( Site 1102), Afula, Not set

Carmel Hospital ( Site 1103), Haifa, Not set

Hadassah Medical Center ( Site 1100), Jerusalem, Not set

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1203), Rozzano, Milano

IRCCS - AOU di Bologna-Istituto di Ematologia "L. e A. Seragnoli" ( Site 1200), Bologna, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1202), Napoli, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 1204), Roma, Not set

Seoul National University Hospital-Oncology ( Site 0302), Seoul, Not set

Samsung Medical Center ( Site 0300), Seoul, Not set

Aotearoa Clinical Trials ( Site 0501), Auckland, Not set

Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku ( Site, Wroclaw, Dolnoslaskie

Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologii i Transplantacji Szpiku ( Site 1304), Lublin, Lubelskie

Pratia MCM Krakow ( Site 1303), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( S, Warszawa, Mazowieckie

Szpitale Pomorskie Sp. z o. o.-Hematology and Bone Marrow Transplantation Department ( Site 1302), Gdynia, Pomorskie

Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 1309), Słupsk, Pomorskie

Pratia Onkologia Katowice ( Site 1306), Katowice, Slaskie

Faculty of Medicine Siriraj Hospital-Division of Hematology, Department of Medicine ( Site 0400), Bangkok, Krung Thep Maha Nakhon

Chulalongkorn University ( Site 0402), Pathumwan, Krung Thep Maha Nakhon

Maharaj Nakorn Chiang Mai Hospital ( Site 0401), Chiang Mai, Not set

Ege University Medicine of Faculty ( Site 1902), Bornova, Izmir

Ankara University Hospital Cebeci-hematology ( Site 1901), Ankara, Not set

Mega Medipol-Hematology ( Site 1909), Istanbul, Not set

Dokuz Eylül Üniversitesi-Hematology ( Site 1905), Izmir, Not set

Ondokuz Mayıs Universitesi ( Site 1907), Samsun, Not set

MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( S, Cherkasy, Cherkaska Oblast

Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Si, Ivano-Frankivsk, Ivano-Frankivska Oblast

Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2002), Lviv, Lvivska Oblast

State non-profit enterprise National Cancer Institute ( Site 2001), Kyiv, Not set

National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine (, Kyiv, Not set

Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 under the Executive Body of Kyiv City Co, Kyiv, Not set

Aberdeen Royal Infirmary ( Site 2104), Aberdeen, Aberdeen City

University College London Hospital-Cancer Clinical Trials Unit ( Site 2100), London-Camden, London, City Of

Conditions: DLBCL, Diffuse Large B-Cell Lymphoma

Learn More ›

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

NCT03147885

Recruiting

This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP. The investigators will establish maximum tolerated dose of Selinexor in combination with RCHOP and also study the efficacy of this combination for therapy of B cell Non-Hodgkin's lymphoma. Giving Selinexor plus chemotherapy may work better in treating patients with B cell non-Hodgkin lym... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/25/2025

Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Conditions: Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Extranodal Marginal Zone Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Stage III Non-Hodgkin Lymphoma, Stage IV Non-Hodgkin Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma

Learn More ›

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686

Recruiting

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/25/2025

Locations: City of Hope Cancer Center, Duarte, California +173 locations

City of Hope Cancer Center, Duarte, California

University of California San Diego Medical Center, La Jolla, California

University of California Los Angeles, Los Angeles, California

St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange, California

Stanford University Medical Center, Stanford, California

Stanford University, Stanford, California

Norwalk Medical Group, Norwalk, Connecticut

Northwest Georgia Oncology Centers PC, Marietta, Georgia

Northwestern University Hospital, Chicago, Illinois

Indiana University, Goshen, Indiana

Kansas University Medical Center, Westwood, Kansas

Louisville Oncology Suburban - Norton Cancer Institute, Louisville, Kentucky

Dana Farber Cancer Center, Boston, Massachusetts

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Battle Creek Health Systm, Battle Creek, Michigan

Karmanos Cancer Institute - Wayne State University, Detroit, Michigan

Washington University, Saint Louis, Missouri

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Hackensack University Medical Center, Hackensack, New Jersey

Weill Medical College of Cornell University, New York, New York

Memorial Sloan-Kettering Cancer Center, New York, New York

Southeastern Medical Oncology Center, Goldsboro, North Carolina

The Ohio State University- James Cancer Hospital, Columbus, Ohio

Willamette Valley Cancer Center, Eugene, Oregon

Kaiser Permanente, Portland, Oregon

University of Pennsylvania Medical Center, Philadelphia, Pennsylvania

Avera Medical Group, Sioux Falls, South Dakota

MD Anderson Cancer Center - University of Texas, Houston, Texas

University of Virginia, Charlottesville, Virginia

University of Washington, Seattle, Washington

West Virginia University, Morgantown, West Virginia

University of Wisconsin Carbone Cancer Center - Wisconsin Institute for Medical Research, Madison, Wisconsin

CEMIC Saavedra, Ciudad Autonoma Buenos Aires, Not set

Fundaleu, Ciudad de Buenos Aires, Not set

Royal Adelaide Hospital, Adelaide, Not set

John Fawkner Cancer Trial Centre, Coburg, Not set

Concord Hospital, Concord, Not set

Austin Health, Heidelberg, Not set

Peter MacCallum Cancer Institute, Melbourne, Not set

Royal Perth Hospital, Perth, Not set

Alfred Hospital, Prahran, Not set

Adventist Health Care Limited trading as San Clinical Trials Unit, Wahroonga, Not set

UZA, Antwerp, Not set

A.Z. Sint Jan, Brugge, Not set

UCL - Saint Luc, Brussels, Not set

UZ Gent - departement oncologie, Gent, Not set

UZ Leuven Gasthuisberg, Leuven, Not set

UCL Mont-Godinne, Yvoir, Not set

Ministerio da Saude Instituto Nacional do Cancer, Rio De Janeiro, Not set

Santa Casa da Misericórdia da Bahia - Hospital Santa Isabel, Salvador, Not set

Instituto de Ensino e Pesquisa São Lucas, Sao Paulo, Not set

Jewish General Hospital, Montreal, Quebec

Peking University People s Hospital, Beijing, Not set

Peking University Third Hospital, Beijing, Not set

Peking University First Hospital, Beijing, Not set

West China Hospital Sichuan University, Chengdu, Not set

Fujian Medical University, Fuzhou, Not set

Sun Yat-sen University Cancer Hospital, Guangzhou, Not set

Zhejiang University First Hospital, Hangzhou, Not set

Ruijin Hospital, Shanghai, Not set

Tangdu hospital the Fourth Military Medical, Shanxi, Not set

The First Affliated Hospital of Soochow University, Suzhou, Not set

The Institute of Hematological disease, Tianjin, Not set

Wuhan Union Hospital, Wuhan, Not set

Fundacion Santa Fe, Bogota, Not set

Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Not set

Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika, Brno, Not set

Fakultni nemocnice Kralovske Vinohrady - Interni hematologicka klinika, Praha 10, Not set

Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie, Praha 2, Not set

Hopital Henri Mondor, Creteil, Not set

Hôpital E. Muller, Mulhouse, Not set

Hopital Necker Enfants Malades, Paris cedex 15, Not set

HOPITAL SAINT LOUIS - Hematology / Oncology, Paris, Not set

Hopital Haut Leveque Service Maladie Du Sang, Pessac, Not set

CH LYON SUD - Hematology, Pierre Benite, Not set

CHU de Tours, Tours, Not set

Vivantes Klinikum Spandau-Klinik f. Innere Medizin Hämatologie/Onkologie/Gastroenterologie - Germany, Berlin, Not set

Universitätsklinikum Carl Gustav Carus; Med. Klinik und Poliklinik I - Hämatologische Ambulanz, Haus, Dresden, Not set

Universitätsklinikum Essen; Klinik f. Hämatologie- Germany, Essen, Not set

Justus-Liebig-Universitaet - Medizinische Klinik IV, Haematologie, Gießen, Not set

Universitätsklinikum Heidelberg Med. Klinik IV, Heidelberg, Not set

Universitätsklinikum des Saarlandes, Homburg/Saar, Not set

Gemeinschaftspraxis Dres. Uhle/Müller/Kröning/Jentsch-Ullrich - Germany, Magdeburg, Not set

OnkoNet Marburg GmbH, Marburg, Not set

Universitätsklinikum für Innere Med. III_Hämatologie, Onkologie...- Germany, Ulm, Not set

Laiko General Hospital - 1st department of Internal Medicine, Athens, Not set

G Papanikolaou Hospital of Thessaloniki, Thessalonikis, Not set

Semmelweis Egyetem, I. Belgyogyaszati Klinika, Budapest N/a, Not set

Szegedi Tudomanyegyetem II. Belgyogyaszati Klinika, Szeged, Not set

St James's Hospital, Dublin, Not set

Haemek Medical Center, Afula, Not set

Hillel Yaffe Medical Center - Oncology, Hadera, Not set

Rambam Health Care Campus, Haifa, Not set

Rabin Medical Center Beilinson Campus, Petah Tikva, Not set

Sheba Medical Center, Ramat-Gan, Not set

Tel Aviv Sourasky Medical Center, Tel Aviv, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set

DIPARTIMENTO DI BIOTECNOLOGIE CELLULARI ED EMATOLOGIA - UNIVERSITà ''LA SAPIENZA'', Roma, Not set

A.O.Citta della Salute e della Scienza di Torino, Torino, Not set

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo ku, Not set

Hiroshima University Hospital, Hiroshima shi, Not set

Hokkaido University Hospital, Sapporo-shi, Not set

National Cancer Center, Goyang-Si, Not set

The Catholic University of Korea Seoul St Mary s Hospital, Seoul, Not set

Oaxaca Site Management Organization S.C., Oaxaca, Not set

VU medisch centrum - Afd.Interne - INT, Amsterdam, Not set

Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza, Brzozow, Not set

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Chorzow, Not set

Uniwersyteckie Centrum Kliniczne, Gdansk, Not set

Pratia MCM Krakow, Krakow, Not set

Oddzial Hematologii, Opole, Not set

Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka, Slupsk, Not set

Katedra I Klinika Hematologii Nowotworow Krwi I Transplantacji Szpiku, Wroclaw, Not set

Instituto Portugues de Oncologia, Lisboa, Not set

Hospital De Santa Maria, Lisbon, Not set

Instituto Portugues de Oncologia, Porto, Not set

Auxilio Mutuo Cancer Center, San Juan, Not set

Arkhangelsk Regional Clinical Hospital, Arkhangelsk, Not set

Chelyabinsk Regiona Onc. Center, Chelyabinsk, Not set

Emergency Hospital of Dzerzhinsk, Dzerzhinsk, Not set

Cancer Research Center, Moscow N/a, Not set

S.P. Botkin Moscow City Clinical Hospital, Moscow, Not set

Regional Clinical Hospital n.a.Semashko, Nizhni Novgorod, Not set

Medical Scientific Radiology - Center, Obninsk, Not set

Perm Medical Sanitary Unit#1, Perm, Not set

Republican Hospital named by V.A.Baranova, Petrozavodsk, Not set

Rostov Research Institute of Oncology, Rostov-Na-Donu, Not set

Ryazan Regional Clinical Hospital, Ryazan, Not set

Leningrad region clinical hospital, Saint, Not set

Samara Region Clinical Hospital, Samara, Not set

Federal Center of Heart, Blood and Endocrinology, Sankt-Peterburg, Not set

Oncological dispensary #2, Sochi, Not set

City Clinical Oncology Dispensary, St. Petersburg, Not set

Clinical Research Institute of Hematology and Transfusiology, St.-Petersburg, Not set

Oncology Dispensary of Komi Republic, Syktyvkar, Not set

Hospital Vall d'Hebron, Barcelona N/a, Not set

Inst. Cat. Doncologia-H Duran I Reynals, L'hospitalet De Llobregat, Not set

Hosp. Univ. de La Princesa, Madrid, Not set

Hosp. Gral. Univ. Gregorio Maranon, Madrid, Not set

Hosp. Univ. Infanta Leonor, Madrid, Not set

Fundacion Jimenez Diaz, Madrid, Not set

Clinica Universitaria de Navarra, Pamplona N/a, Not set

Hospital Clinico Universitario Salamanca, Salamanca, Not set

Sahlgrenska University hospital, Hematology Dept, Göteborg, Not set

Skanes universitetssjukhus, Lund, Not set

Karolinska Universitetssjukhuset Solna, Centrum för Hematologi, Stockholm, Stockholm, Not set

Changhua Cristian Hospital, Changhua County, Not set

Ankara University, Ankara, Not set

American Hospital, Istanbul, Not set

Istanbul University, Istanbul, Not set

Dokuz Eylul Universitesi Tip Fakultesi, Izmir, Not set

Erciyes University, Kayseri, Not set

Communal Nonprofit Enterprise 'Cherkasy Regional Oncology Dispensary Of Cherkasy Regional Council', Cherkasy, Not set

Dnepropetrovsk City Clinical Hospital #4, Regional Hematology Center, Dnepropetrovsk, Not set

SI Grigoriev Institute for Medical Radiology National Academy of Medical Science of Ukraine, Kharkiv, Not set

Khmelnitskiy Regional Hospital, Hematology Department, Khmelnitskiy, Not set

State Institution Scientific Center for Radiation Medicine Academy of Medical Sciences of Ukraine, Kiev, Not set

Institute of Blood Pathology and Transfusion Medicine of AMS of Ukraine, Lviv, Not set

Vinnytsya Regional Clinical Hospital named after M.I.Pirogov, Vinnitsa, Not set

University Hospitals Birmingham NHS Trust,, Birmingham, Not set

Royal Bournemouth Hospital, Bournemouth, Not set

Colchester Hospital University NHS, Colchester, Not set

Beatson West Of Scotland Cancer Centre, Glasgow, Not set

St James's Institute of Oncology, Leeds, Not set

Leicester Royal Infirmary - Haematology, Leicester, Not set

St Bartholomew's Hospital - Dept of Haematology, London, Not set

University College London Hospitals NHSFT, London, Not set

Kings College Hospital, London, Not set

Christie Hospital, Manchester, Not set

Nottingham University Hospitals NHS Trust, Nottingham, Not set

Derriford Hospital, Plymouth, Not set

Royal Hallamshire Hospital, Sheffield, Not set

Southampton General Hospital, Southampton, Not set

Royal Marsden Hospital (Sutton), Sutton, Not set

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease

Learn More ›

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT06806033

Recruiting

The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitamab + gemcitabine + oxaliplatin (Glofit-GemOx) followed by glofitamab-only treatment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/18/2025

Locations: Alaska Oncology & Hematology, LLC, Anchorage, Alaska +9 locations

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

1 - 12 of 33